Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
MediWound Ltd. - Ordinary Shares
(NQ:
MDWD
)
17.27
+0.15 (+0.88%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about MediWound Ltd. - Ordinary Shares
< Previous
1
2
3
4
5
6
7
Next >
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
April 25, 2024
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Ltd. (NASDAQ: MDWD) Sets New 52-Week High in Wednesday Session
April 17, 2024
Via
Investor Brand Network
MDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q4 2023
↗
March 21, 2024
MDWD stock results show that MediWound beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
March 21, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Preview: MediWound's Earnings
↗
March 20, 2024
Via
Benzinga
Recap: MediWound Q3 Earnings
↗
November 21, 2023
Via
Benzinga
Earnings Outlook For MediWound
↗
November 20, 2023
Via
Benzinga
HC Wainwright & Co. Maintains Buy Rating for MediWound: Here's What You Need To Know
↗
September 21, 2023
Via
Benzinga
What 4 Analyst Ratings Have To Say About MediWound
↗
August 17, 2023
Via
Benzinga
Earnings Scheduled For March 21, 2024
↗
March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million.
Via
Benzinga
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
March 14, 2024
Conference Call and Webcast Scheduled for Thursday, March 21st at 8:30 am Eastern Time
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
February 12, 2024
Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients...
From
MediWound Ltd.
Via
GlobeNewswire
MediWound to Participate in Two Upcoming Investor Conferences
February 05, 2024
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
January 09, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Innovative Burn Care: MediWound Bags Additional DoD Grant For NexoBrid Development
↗
December 28, 2023
Biopharmaceutical company MediWound Ltd (NASDAQ: MDWD) reported that the U.S.
Via
Benzinga
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
December 28, 2023
Awarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 million
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
December 21, 2023
Results show EscharEx to be safe and effective, and suggest it can go beyond traditional expectations for enzymatic debridement
From
MediWound Ltd.
Via
GlobeNewswire
Earnings Scheduled For November 21, 2023
↗
November 21, 2023
Companies Reporting Before The Bell • Golden Ocean Group (NASDAQ:GOGL) is likely to report quarterly earnings at $0.11 per share on revenue of $149.42 million.
Via
Benzinga
MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update
November 21, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
November 21, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound to Report Third Quarter 2023 Financial Results
November 14, 2023
Conference Call and Webcast Scheduled for Tuesday, November 21st at 8:30 am Eastern Time
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients
November 13, 2023
The label expansion will solidify NexoBrid’s position in the EU as a safe and effective non-surgical treatment for burn patients of all ages
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe
November 08, 2023
NexoBrid complements PMI’s portfolio, allowing it to provide a comprehensive solution for burn patients
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces Collaboration with 3M on EscharEx® Phase III Study
October 11, 2023
MediWound to join forces with 3M Health Care, world’s largest wound care company in pivotal study for patients with venous leg ulcers
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Deploys NexoBrid® for Emergency Supply
October 09, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Q4 Stock Predictions: 3 Micro-Cap Stocks Ready to Skyrocket Into 2024
↗
October 03, 2023
These Q4 micro-cap stocks are the ones to buy in on for long-term growth and returns to any investor's portfolio.
Via
InvestorPlace
MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
September 21, 2023
Full commercial launch of NexoBrid marks important first step to becoming the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns
From
MediWound Ltd.
Via
GlobeNewswire
MediWound’s NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association Congress
September 11, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound to Participate in Fireside Chat at H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update
August 15, 2023
From
MediWound Ltd.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
